Meet with top Israeli leaders at the Jerusalem Post Annual Conference 2017
Teva to set up Israeli drug development VC fund
ByGALI WEINREB, SHIRI HABIB-VALDHORN/GLOBES
September 16, 2011 06:05

Teva Pharmaceutical Industries Ltd's (Nasdaq: TEVA; TASE: TEVA) acquisition of Cephalon Inc. (Nasdaq: CEPH) is causing far-reaching changes in Teva's brand drug operations. Sources inform ''Globes'' that Teva plans to set up a venture capital fund to invest in Israeli drug development companies.

Teva Innovative Ventures head Dr. Aharon Schwartz will be responsible for investing in start-ups and reaching licensing agreements with universities as part of the company's effort to expand its pipeline of innovative drugs.

Teva has already invested in several Israeli drug development start-ups. Investing through a corporate venture capital fund, rather than directly, has significant implications. A venture capital fund will be a legal and corporate entity separate from Teva. This should ease fears of potential target companies that accepting money from Teva might deter other potential investors.

Share this article via
from around the web
Related Content
Breaking news
March 27, 2017
Center-right party wins 32.6 pct in Bulgarian election, 90 pct of votes counted

By REUTERS

Top Stories
Israel Weather
  • 10 - 24
    Beer Sheva
    11 - 19
    Tel Aviv - Yafo
  • 11 - 21
    Jerusalem
    10 - 19
    Haifa
  • 16 - 30
    Elat
    12 - 25
    Tiberias